As a market, nanomedicine holds promise owing to its highly precise and reliable nature. Clinical oncology nanomedicine applications dominated the overall market in 2013, however, the cardiovascular nanomedicine market is expected to be the fastest growing segment during the forecast period.
Drivers and Restraints
Increasing research funding, growing incidence of cardiovascular diseases, rising geriatric population, awareness of nanomedicine application, high unmet medical needs, and increasing competition by the entry of new players are some of the major drivers for the growth of this market. However, the high costs of nanotechnology-based medical devices and time-consuming product approval are turning out to be restraints for the market.
Venture capital funding share of nanotechnology vs. other sectors in 2007
Venture capital funding share of nanotechnology vs. other sectors in 2009
Global Healthcare Nanotechnology (Nanomedicine) Market Segmentation
The nanomedicine market is segmented by:
The applications segment is further segmented into drug delivery, drugs, biomaterials, active implants, in-vitro diagnostics, and in-vivo imaging. Currently, the drug delivery sub-segment holds the larger share as compared to the others because of the higher efficacy of nanomaterials and their ability to cross through the blood with minimum invasiveness and increased bioavailability. This trend is expected to continue throughout the forecast period, as nanoparticles are finding increasing usage in cancer therapy. By disease, the market is sub-segmented into neurological diseases, cardiovascular diseases, oncology, anti-inflammatory, anti-infective, and others, with obesity and diarrhea being the largest sub-segments.
Geographically, the market is segmented into North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America. Currently, North America accounts for the largest market share. However, Europe is expected to grow at a faster rate than North America due to the extensive product pipeline portfolio and constantly improving regulatory framework. The Asia-Pacific region is expected to grow at the highest CAGR during the forecast period, owing to the improving research infrastructure in the region, improved purchasing power of patients, the rapid increase in geriatric population, and rising awareness regarding healthcare. China and India are expected to be the fastest growing nanomedicine markets in Asia.
Increased research spending in the product and technology sectors is a potential driver for the market in the forecast period. Minimal awareness regarding the beneficial use of microbiome-based products may act as a restraint for the growth of this market.
The key players in the market are:
Market analysis for the global nanomedicine market, with region-specific assessments and competition analysis.
Market definition along with the identification of key drivers, restraints, opportunities, and challenges.
Identification of factors instrumental in changing the market scenario, rising prospective opportunities, and identification of key companies that can influence this market on a global and regional scale.
Extensively researched competitive landscape section with company profiles of key players with the analysis of their current strategic interests and key financial information.
Identification and analysis of the macro and micro factors that affect the global nanomedicine market.
Insights of the market in the regions that have the highest potential for growth and to also identify the markets that are still untapped.
1.1 Study Deliverables
1.2 Market Definition
1.3 Sizing Units
1.4 Base Currency
1.5 Review and Forecast Period Years
1.6 General Study Assumptions
1.7 Report Description
2. Research Methodology
2.2 Analysis Methodology
2.3 Study Timeline
2.4 Study Phases
2.4.1 Secondary Research
2.4.2 Discussion Guide
2.4.3 Market Engineering & Econometric Model
2.4.4 Expert Validation
3. Executive Summary
4. Key Inferences
5. Market Overview and Industry Trends
5.1 Current Market Scenario
5.2 Porterâ€™s Five Force Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Buyers
5.2.3 Degree of Competition
5.2.4 Threat of Substitution
5.2.5 Threat of New Entrants
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Increasing Research Funding
6.1.2 Increasing Incidence of Cardiovascular Diseases
6.1.3 Rising Geriatric Population
6.1.4 Awareness of Nanomedicine Application
6.1.5 High Unmet Medical Needs
6.1.6 Increasing Competition by Entry of New Players
6.2 Market Restraints
6.2.1 High Costs of Nanotechnology-Based Medical Devices
6.2.2 Time-Consuming Product Approval
6.3 Market Opportunities
6.3.1 Increasing Application in Cancer Therapy
6.4 Key Challenges
7. Global Healthcare Nanotechnology (Nanomedicine) Market -Segmentation
7.1 By Applications
7.1.1 Drug Delivery
7.1.4 Active Implants
7.1.5 In-Vitro Diagnostic
7.1.6 In-Vivo Imaging
7.2 By Disease
7.2.1 Neurological Diseases
7.2.2 Cardiovascuar Diseases
8. Global Healthcare Nanotechnology (Nanomedicine) By Geography - Regional Share and Forecasts
8.1 North America
8.1.1 United States
8.2.5 Spain & Portugal
8.2.8 Rest of Europe
8.3.4 Australia & New Zealand
8.3.5 South Korea
8.3.6 Rest of Asia-Pacific
8.4 Middle East & Africa
8.4.2 South Africa
8.4.3 Rest of Middle East & Africa
8.5 Latin America
8.5.3 Rest of Latin America
9. Competitive Landscape
9.1 Merger and Acquisition Analysis
9.2 New Product Launches
9.3 Agreements, Collaborations & Partnerships
10. Company Profiles
10.1 Abbott Laboratories
10.2 CombiMatrix Corporation
10.3 GE Healthcare
10.4 Sigma-Tau Pharmaceuticals, Inc.
10.5 Johnson & Johnson
10.6 Mallinckrodt PLC
10.7 Merck & Company, Inc.
10.8 Nanosphere, Inc.
10.9 Pfizer, Inc.
10.10 Celgene Corporation
10.11 Teva Pharmaceutical Industries Ltd.
10.12 UCB (Union chimique belge) S.A.
11. Analyst Outlook for Investment Opportunities
12. Future Outlook of the Market